AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian CancerGlobeNewsWire • 11/10/25
AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) MeetingGlobeNewsWire • 11/04/25
All You Need to Know About AIM ImmunoTech (AIM) Rating Upgrade to BuyZacks Investment Research • 10/10/25
AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint InhibitorsGlobeNewsWire • 09/25/25
AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in PolandGlobeNewsWire • 09/04/25
AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/15/25
AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTechGlobeNewsWire • 08/14/25
AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)GlobeNewsWire • 08/06/25
AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer ApprovalGlobeNewsWire • 08/04/25
AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology TherapiesGlobeNewsWire • 07/02/25
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity RequirementsGlobeNewsWire • 06/20/25
AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®GlobeNewsWire • 06/12/25
AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of ImmunologistsGlobeNewsWire • 05/08/25
AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open MarketGlobeNewsWire • 04/07/25
NYSE American to Commence Delisting Proceedings Against AIM ImmunoTech Inc. (AIM)Business Wire • 04/04/25